Phase 1 Prostate Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with a specific type of prostate cancer (adenocarcinoma) confirmed by a tissue or cell sample, where the cancer is no longer responding to hormone treatment — but not a pure small cell type.
- People whose prostate cancer has spread to other parts of the body, is no longer responding to hormone therapy (castration-resistant), has a PSA blood test result of 4 ng/mL or higher at the screening visit, and has shown signs of getting worse within the 6 months before screening.
- People who have already received at least 2 rounds of approved systemic (whole-body) treatments for their prostate cancer — beyond standard hormone-lowering therapy — including at least one newer type of anti-androgen medicine such as abiraterone, enzalutamide, apalutamide, or darolutamide.
- People who have either had surgical removal of the testicles, or are currently receiving hormone-lowering injections or medicines that keep testosterone levels very low (below 50 ng/dL), and who are willing to continue that treatment throughout the study.
Who may not be able to join:
- People who have bone lesions that are considered structurally unstable and at risk of fracturing.
- People who have signs or imaging evidence of blood clots — such as a deep vein clot or a clot in the lungs — that have not been fully treated (confirm with trial site for details on prior clotting history and what treatments may allow participation).
- People whose kidneys are not functioning well enough, based on a specific measurement of kidney filtering ability falling below a certain level.
- People whose liver is not functioning well enough, based on blood test results for certain liver enzymes and bilirubin being above set limits (the exact limits vary depending on whether cancer has spread to the liver — confirm with trial site).
- People whose bone marrow is not producing enough blood cells, specifically if white blood cell or platelet counts are below set levels — including specific waiting periods after certain blood-boosting medications or platelet transfusions (confirm with trial site for exact timing requirements).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Clinical Trial Management, Regeneron Pharmaceuticals
Phone: 844-734-6643
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Occurrence of Treatment Emergent Adverse Events (TEAEs); Occurrence of Dose Limiting Toxicities (DLTs); Occurrence of Adverse Events of Special Interest (AESIs)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 12 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.